转移性胃癌治疗的新进展：聚焦于曲妥珠单抗。
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab.
作者信息
Rose Jeffrey S, Bekaii-Saab Tanios S
机构信息
Department of Internal Medicine, Division of Medical Oncology, The Ohio State University - Arthur James Cancer Hospital, Columbus, OH, USA.
出版信息
Onco Targets Ther. 2011 Mar 24;4:21-6. doi: 10.2147/OTT.S10188.
Abstract
Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.
摘要
转移性胃癌患者的预后较差。新的化疗联合方案的研发使总生存期稳步提高，但幅度有限，两药和三药方案的疗效最为显著。曲妥珠单抗是一种针对人表皮生长因子受体2（HER2）的全人源化单克隆抗体，已被发现可提高晚期胃癌患者的缓解率并延长生存期。本综述将阐述HER2的作用，并总结曲妥珠单抗在晚期胃癌治疗中的进展。
相似文献
1
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab.转移性胃癌治疗的新进展：聚焦于曲妥珠单抗。
Onco Targets Ther. 2011 Mar 24;4:21-6. doi: 10.2147/OTT.S10188.
2
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.曲妥珠单抗-德鲁替康：在胃癌或胃食管结合部腺癌中的应用评价。
Target Oncol. 2023 Nov;18(6):981-989. doi: 10.1007/s11523-023-00998-y. Epub 2023 Oct 3.
3
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.曲妥珠单抗治疗人表皮生长因子受体 2 阳性胃或胃食管结合部转移性腺癌的临床观察。
Oncologist. 2020 Aug;25(8):e1181-e1187. doi: 10.1634/theoncologist.2020-0109. Epub 2020 Jun 4.
4
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.曲妥珠单抗治疗晚期胃及胃食管结合部腺癌：成就与困境。
Curr Treat Options Oncol. 2021 Aug 23;22(10):88. doi: 10.1007/s11864-021-00884-7.
5
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.转移性胃癌患者的治疗选择：现状与未来展望
World J Gastroenterol. 2014 Apr 14;20(14):3905-15. doi: 10.3748/wjg.v20.i14.3905.
6
Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.HER2 阳性晚期胃癌和胃食管交界癌的治疗进展。
J Clin Gastroenterol. 2012 Sep;46(8):637-48. doi: 10.1097/MCG.0b013e3182557307.
7
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 阳性胃癌。
N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.
8
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.一线帕博利珠单抗/安慰剂联合曲妥珠单抗和化疗治疗 HER2 阳性晚期胃癌：KEYNOTE-811 研究。
Future Oncol. 2021 Feb;17(5):491-501. doi: 10.2217/fon-2020-0737. Epub 2020 Nov 10.
9
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.曲妥珠单抗治疗后 HER2+转移性胃癌的生存、安全性和临床结局的回顾。
Cancer Treat Res Commun. 2020;24:100189. doi: 10.1016/j.ctarc.2020.100189. Epub 2020 Jun 30.
10
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
引用本文的文献
1
Current trends and future prospects of drug repositioning in gastrointestinal oncology.胃肠道肿瘤药物重新定位的当前趋势与未来前景
Front Pharmacol. 2024 Jan 4;14:1329244. doi: 10.3389/fphar.2023.1329244. eCollection 2023.
2
Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway.蛇床子素通过诱导凋亡和抑制AKT-MAPK通路，与HER2抑制剂曲妥珠单抗协同作用于HER2过表达的N87胃癌细胞。
Front Pharmacol. 2018 Nov 27;9:1392. doi: 10.3389/fphar.2018.01392. eCollection 2018.
3
Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.免疫组织化学评估HER2在接受胃癌根治性切除术患者中的临床应用价值。
Onco Targets Ther. 2016 Feb 26;9:949-58. doi: 10.2147/OTT.S100979. eCollection 2016.
4
Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes.通过受体酪氨酸激酶和化疗敏感性基因的共同调控表达来界定胃癌亚型
Am J Transl Res. 2015 Aug 15;7(8):1429-39. eCollection 2015.
5
Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis.1998年至2009年转移性胃癌患者的总体生存率有适度提高：一项基于人群的监测、流行病学和最终结果（SEER）分析。
Gastric Cancer. 2016 Jul;19(3):723-34. doi: 10.1007/s10120-015-0541-9. Epub 2015 Sep 21.
6
Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.分选酶介导的具有高体外和体内活性的位点特异性缀合抗体药物偶联物的生成。
PLoS One. 2015 Jul 1;10(7):e0131177. doi: 10.1371/journal.pone.0131177. eCollection 2015.
7
Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.胃癌个体化治疗：分子机制与新型靶向治疗。
World J Gastroenterol. 2013 Oct 14;19(38):6383-97. doi: 10.3748/wjg.v19.i38.6383.
8
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.部分具有 EGFR 扩增和过表达的胃癌对西妥昔单抗治疗有反应。
Sci Rep. 2013 Oct 21;3:2992. doi: 10.1038/srep02992.
9
Metastatic gastric cancer treatment: a little slow but worthy progress.转移性胃癌治疗：进展虽缓，但值得期待。
Med Oncol. 2013 Mar;30(1):464. doi: 10.1007/s12032-013-0464-4. Epub 2013 Jan 20.
10
Drug repositioning for personalized medicine.用于个性化医疗的药物重新定位。
Genome Med. 2012 Mar 30;4(3):27. doi: 10.1186/gm326. eCollection 2012.
本文引用的文献
1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌（ToGA）：一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
2
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.曲妥珠单抗在转移性乳腺癌患者常规临床实践及进展后的疗效：观察性 Hermine 研究。
Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.
3
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.胃癌中HER2的表达：罕见、异质性且无预后价值——来自两个独立系列924例病例的结论
Cell Oncol. 2010;32(1-2):57-65. doi: 10.3233/CLO-2009-0497.
4
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.紫杉醇和曲妥珠单抗联合白细胞介素-12 治疗 HER2/neu 表达的恶性肿瘤的 I 期临床试验。
Mol Cancer Ther. 2009 Nov;8(11):2983-91. doi: 10.1158/1535-7163.MCT-09-0820. Epub 2009 Nov 3.
5
Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.胃癌中HER2/neu和HER3过表达的比较研究
World J Surg. 2009 Oct;33(10):2112-8. doi: 10.1007/s00268-009-0142-z.
6
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.新型抗癌靶点：重新审视ERBB2并发现ERBB3。
Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18.
7
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.曲妥珠单抗用于人表皮生长因子受体2阳性晚期乳腺癌进展后的治疗：德国乳腺癌研究组26/国际乳腺癌研究组03-05研究
J Clin Oncol. 2009 Apr 20;27(12):1999-2006. doi: 10.1200/JCO.2008.19.6618. Epub 2009 Mar 16.
8
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.胃癌患者中ERBB2基因状态与组织病理学参数及疾病特异性生存的相关性
Br J Cancer. 2009 Feb 10;100(3):487-93. doi: 10.1038/sj.bjc.6604885. Epub 2009 Jan 20.
9
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.胰岛素样生长因子1型受体和表皮生长因子受体在晚期胃癌患者中的临床意义
Oncology. 2008;74(1-2):76-83. doi: 10.1159/000139127. Epub 2008 Jun 11.
10
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.胰岛素样生长因子1型受体、表皮生长因子受体和HER2表达对胃癌患者预后的影响。
Clin Cancer Res. 2008 May 15;14(10):3022-9. doi: 10.1158/1078-0432.CCR-07-1898.
Zotero 插件